Welcome to our dedicated page for Establishment Labs Holdings news (Ticker: $ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Establishment Labs Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Establishment Labs Holdings's position in the market.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported first quarter 2024 financial results, with worldwide revenue of $37.2 million. The 2024 revenue guidance is $174 million to $184 million, reflecting a 5% to 11% increase over 2023. Gross profit was $24.4 million, with a loss from operations of $8.8 million. Adjusted EBITDA loss improved to $3.7 million. The company's cash balance was $73.0 million as of March 31, 2024. Establishment Labs presented 4-year results from Motiva® U.S. IDE study showing positive outcomes, aiming for FDA approval of Motiva Implants in 2024.
Establishment Labs Holdings Inc. noted the presentation of 4-year results from the Motiva US IDE Study at The Aesthetic Meeting 2024. Dr. Caroline Glicksman presented data for 451 primary augmentation patients, showing low complication rates and high patient follow-up, with Motiva implants potentially becoming a new standard in breast aesthetics.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announces the appointment of Jeff Ehrhardt as the General Manager of North America. Mr. Ehrhardt brings over 25 years of experience from Allergan Aesthetics, with the responsibility of launching Motiva implants in the U.S. to set new standards in breast aesthetics and reconstruction. The move signifies a significant step for Establishment Labs in expanding its global presence and enhancing women's health and wellness.